Oral sulfonylureas and CV mortality

Geriatrics

Volumn 59, Issue 9, 2004, Pages

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG MECHANISM; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SHORT SURVEY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADMINISTRATION, ORAL; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; SULFONYLUREA COMPOUNDS;

EID: 19344366198     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (20)

1. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 1975; 24(suppl 1):65-184.
2. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972; 21(9):976-9.
3. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837-53.
4. Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997; 96(1):29-32.
5. Narishige T, Egashira K, Akatsuka Y, et al. Glibenclamide prevents coronary vasodilation induced by beta 1-adrenoceptor stimulation in dogs. Am J Physiol 1994; 266(1 Pt 2):H84-92.
6. ATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996; 94(9):2297-301.
7. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90(2):700-5.
8. Brady PA, Terzic A. The sulfonylurea controversy: More questions from the heart. J Am Coll Cardiol 1998; 31(5):950-6.
9. Khawaja U, Campeau R, Tenaglia A, et al. Prevention of ischemic preconditioning in diabetic patients with CAD treated with sulfonylureas (abstract). J Am Coll Cardiol 2000; 35:339A.
10. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103(25):3111-6.
11. Wilde AA. ATP-sensitive potassium channels, transmural ischemia and the ECG implications for the non-insulin dependent diabetic patient? Cardiovasc Res 1996; 31(5):688-90.
12. Kubota I, Yamaki M, Shibata T, Ikeno E, Hosoya Y, Tomoike H. Role of ATP-sensitive K+ channel on ECG ST segment elevation during a bout of myocardial ischemia. Circulation 1993; 88(4 Pt 1):1845-51.
13. Kondo T, Kubota I, Tachibana H, Yamaki M, Tomoike H. Glibenclamide attenuates peaked T wave in early phase of myocardial ischemia. Cardiovasc Res 1996; 31(5):683-7.
14. Huizar JF, Gonzalez LA, Alderman J, Smith HS. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. J Am Coll Cardiol 2003; 42(6):1017-21.
15. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33(1):119-24.
16. O'Keefe JH, Blackstone EH, Sergeant P, McCallister BD. The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J 1998; 19(11):1696-703.
17. O'Keefe JH Jr, Miles JM, Harris WH, Moe RM, McCallister BD. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc 1999; 74(2):171-80.
18. Aronow WS, Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 2001; 88(5):556-7.
19. Jollis JG, Simpson RJ Jr, Cascio WE, Chowdhury MK, Crouse JR 3rd, Smith SC Jr. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138(5 Pt 1):S376-80.
20. Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995; 28(suppl):S115-37.